ABSTRACT A radioaerosol technique has been used to investigate whether the size distribution of aerosols released from a jet nebuliser affects the amount of aerosol delivered to the lungs. Six subjects with mild asthma (FEV1 81% of predicted) were studied on three occasions. On each visit they received one of three aerosols tagged with technetium-99m in 0-9% saline. The aerosols were generated by either (A) a Turret nebuliser operated at 8 1 min-1 (mass median diameter (MMD) 1-8 um); (B) an Upmist nebuliser operated at 6 1 min ' (MMD 4-6 gm); or (C) an Inspiron Mini-neb operated at 4 1 min-1 (MMD 10X3 pm). The aerosols were given in a randomised single blind manner and inhaled under identical conditions of inspiratory volume and frequency. The mean (SD) percentage of aerosols A, B, C released from the nebulisers during inhalation that was recovered in an expiratory filter was 23 (6), 25 (4), and 24 (4) respectively. Of the aerosols released from the nebuliser and deposited in the body, the percentage deposited in the lung was 79 (3) for aerosol A, 59 (4) for aerosol B, and 44 (5) for aerosol C. The remaining aerosol was deposited in the oropharynx and swallowed. It is concluded that small nebulised aerosols (MMD < 2 um) deliver a larger dose to the lungs and should be used to maximise lung deposition.
Jet nebulisers are frequently used to deliver solutions of aqueous drugs to the lungs in aerosol form. A wide variety of nebulisers is available, with little uniformity in their usage. It has been shown that the size distribution of aerosols released varies considerably between nebulisers, and that the flow rate of compressed gas used to drive the nebuliser directly affects the size of the aerosol, a reduction in aerosol size occurring with increased flow rate.'
The size distribution of an aerosol is known to be a primary determinant of the amount that reaches the lungs during inhalation. Pulmonary deposition increases with decreasing particle size down to 0O5 gm below which an aerosol has a high airborne stability and tends to be exhaled without being deposited.2 It is generally accepted that lung deposition is greater with particles in the size range 2-5 um,3 particularly in obstructive lung disease, where the airways are narrowed and an aerosol will penetrate less deeply.4 Rees et Effect of nebulised aerosol size on lung deposition in patients with mild asthma FEV, 813% (2%) of the value predicted for their age, sex, and height, and the mean coefficient of variation of their FEV, between studies 4-95%. All subjects were life long non-smokers or ex-smokers and all were regular users of inhaled f agonist aerosols only. These were withdrawn 12 hours before each study. We obtained the permission of the local ethical committee for the investigation and informed written consent from each subject.
RADIOAEROSOL
Technetium-99m (99mTcO4-) in 0-9% saline (0-32 mol/l NaCl) was used as the radioaerosol. This solution has been used previously9 10 and has been shown not to affect the droplet size of aerosol from the nebuliser. Because of its small molecular weight, however, the solution is cleared rapidly from the lung by diffusion." For this reason the radioaerosol was inhaled with the subjects seated in front of a gamma camera so that the entire imaging procedure could be completed within seven minutes of their starting the inhalation. This is within the half time of the solution in the lung." The radiation dose to the subjects resulting from inhalation of 500,uCi of 99mTcO4j in this form was estimated to be 6-1 mrad to the lungs and 0-24 mrad to the whole body.12 NEBULISERS Three different makes of nebuliser operated under three different flow rates of compressed air were used to generate the three radioaerosols. Nebuliser selection was made on the basis of previous work' and the nebulisers used were those used in a recent study to compare bronchodilator efficacy of nebulised terbutaline aerosols.6 Each nebuliser was characterised for its aerosol output and size distribution before use by a Malvern laser particle sizer by a technique previously described.' Aerosol A was generated by a Turret nebuliser operated at 8 1 min-. The resulting aerosol was found to have a MMD of 1 8 pm with 80% of the aerosol mass contained in droplets smaller than 5 pm. Aerosol B was generated by an Upmist nebuliser operated at 6 1 min-, and this gave an accoustic signal generator aerosol with an MMD of 4 6pm with 50% of the aerosol mass contained in particles smaller than 5 gm. Aerosol C was generated by an Inspiron Mini-neb nebuliser driven at 4 1 min'-; this gave an aerosol with an MMD of 10-3 pm and with 20% of the aerosol mass in particles smaller than 5 gm.
STUDY DESIGN
The three aerosols were given in a randomised, single blind manner, with a minimum interval of three days between studies. Each study started at the same time of day.
On arrival subjects had their baseline lung function measurements recorded. FEV1 and forced vital capacity (FVC) were measured by Vitalograph; peak expiratory flow (PEF) by Wright peak flow meter; and maximum flow at 50% and 25% of vital capacity (Vmax5o and Vmax25) by an Ohio dry spirometer linked to a Gould XY Plotter. The subjects were then seated with their backs against a large field of view gamma camera linked to a Nodecrest computer. An image of regional ventilation was obtained with krypton-81m ("lmKr) in the posterior view to delineate the lung outlines for subsequent analysis of the radioaerosol scans. After the "tmKr image had been obtained the subjects inhaled the radioaerosol, remaining seated in the same position (fig 1) . Their nostrils were occluded by a noseclip and they inhaled the aerosol directly from the nebuliser through a mouthpiece. The nebuliser and an expiratory filter were housed in a lead lined box. The subjects regulated their breathing by means of an audible electronic device that signalled 14 breaths a minute, inspiration lasting one third of the cycle. Inspired air was inhaled through a Voldyne Volumetric Exerciser, which enabled the subjects to regulate their inspired volume to 700 ml. Exhaled air passed through a one way valve and into an expiratory filter to trap any exhaled radioaerosol. The radioaerosol was released from the nebuliser during inspiration only by the use of a triggering device on the air line to the nebuliser.
The radioaerosol inhalation took place over 120 seconds. Immediately afterwards the nebuliser and equipment were removed from the proximity of the gamma camera and an image of the regional deposition of the aerosol within the lungs was obtained over 120 seconds. The gamma camera was then raised and another image of oropharyngeal deposition obtained over 120 seconds. The entire imaging procedure was completed within seven minutes from the start of inhalation.
ANALYSIS
The amount of radioaerosol released from the nebulisers during the inhalation procedure was measured by weighing the nebuliser before and after inhalation. The amount of exhaled radioaerosol was measured by counting the activity in the expiratory filter with a scintillation counter. The expired radioaerosol was then deducted from the amount of radioaerosol released from the nebuliser during inhalation, enabling the proportion of exhaled radioaerosol to be estimated. The images of radioaerosol deposition were stored in the computer and subsequently analysed by identifying "regions of interest" that included the lungs, stomach, oesophagus, trachea, and oropharynx.
Non-parametric statistical tests were applied, the Friedman analysis of variance to identify differences between the three treatments and the Wilcoxon rank sum test for paired data to identify differences between individual treatments.'3 A p value of < 0 05 was taken to indicate statistical significance.
Results
The pulmonary function indices recorded on the three study days for the six patients are shown in table 1.
There was no statistical difference between baseline pulmonary function on the three occasions. The percentage of the radioaerosol released from the nebulisers but retained in the expiratory filter was 23 (6) for aerosol A, 25 (4) for aerosol B, and 24 (4) for aerosol C; the differences were not significant (p > 0 05). Figure 2 shows the distribution of the three radioaerosols in one subject. There is a considerable reduction in pulmonary aerosol deposition with increased aerosol MMD (aerosol A > aerosol B > aerosol C) and an associated increase in oropharyngeal deposition. Aerosol deposited in the oropharynx was subsequently swallowed and can be seen in the stomach.
The difference in pulmonary deposition between the three radioaerosols was significant (p < 0 05). 
